Capsa Healthcare has introduced RoboPharma, powered by Axona, an integrated automation and enterprise software platform designed to support centralised pharmacy operations, including

AbCellera has entered into a collaboration with Vertex Pharmaceuticals to discover, develop, manufacture and commercialise multispecific T-cell engagers (TCEs) for the treatment of autoimmune

DKSH Healthcare has expanded its strategic partnership with Novartis in South Korea by adding the hypertension medicines Diovan® and Exforge® to its prescription drug portfolio. Under the agreement

Argenx has entered into a definitive agreement to acquire Forte Biosciences in an all-cash transaction valued at approximately US$2.2 billion.

Bora Pharmaceuticals and Onconic Therapeutics have entered into a manufacturing agreement to support the U.S. clinical development of JAQBO, a potassium-competitive acid blocker (P-CAB)

Dassault Systèmes has signed a definitive agreement to acquire ArisGlobal in a deal valued at approximately US$1.8 billion in cash, with up to an additional US$200 million linked to multi-year AI-related revenue milestones.

Restore Vision has entered into a development and manufacturing partnership with Forge Biologics to support the advancement of RV-001, its investigational adeno-associated virus (AAV) gene therapy

Samsung Biologics has announced an all-cash public tender offer to acquire 100% of the share capital of PolyPeptide Group AG, a global contract development and manufacturing organisation (CDMO) specialising in peptide

Excalipoint Therapeutics has entered into a strategic partnership with DP Technology to co-develop a proprietary artificial intelligence (AI)-powered platform for the discovery of T-cell engagers (TCEs) and multi-specific antibodies.

Samsung Bioepis and Organon have expanded their Development and Commercialisation Agreement to introduce an additional biosimilar product in Australia through Organon ANZ.